CALGARY, Sept. 30 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,429,485 entitled "Method of Producing Infectious Reovirus". The claims cover methods of purifying reassorted reovirus from an FDA-approved cell line.
"This patent provides broad protection for methods of producing reassorted reovirus," said Mary Ann Dillahunty, Vice President of Intellectual Property for Oncolytics. "It expands our already substantial portfolio of patents which cover the production of therapeutic reovirus."
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com
This news release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including among others, the Company's belief as
to the importance of the issuance of this patent, the safety and efficacy
of the reovirus, the Company's expectations as to the potential
applications of the patented technology and other statements relating to
anticipated developments in the Company's business and technologies,
involve known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the efficacy of REOLYSIN(R) as a cancer treatment, the success and
timely completion of clinical studies and trials, uncertainties rela
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved